References
- Basaria S. Male hypogonadism. Lancet. 2014;383:1250–1263.
- Dohle G, Arver S, Bettocchi C, et al. Guidelines on male hypogonadism: European Association of Urology. [ cited 2012]. Available from: http://www uroweb org/gls/pdf/16_Male_Hypogonadism_LR%20II pdf, 2012.
- Morales A, Bella AJ, Chun S, et al. A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. Can Urol Assoc J. 2010;4(4):269–275.
- FDA Drug Safety Communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. [ cited 2014 Jan 31]. Available from: http://www fda gov/Drugs/DrugSafety/ucm383904 htm, 2014.
- Bhasin S, Cunningham G, Hayes F, al e Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–359.
- Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male: Official J Int Soc Study Aging Male. 2009;12:5–12.
- Xu L, Freeman G, Cowling B, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
- Handelsman DJ. Global trends in testosterone prescribing. 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199(8):548–551.
- Hall SA, Ranganathan G, Tinsley LJ, et al. Population-based patterns of prescription androgen use, 1976-2008. Pharmacoepidemiol Drug Saf. 2014;23(5):498–506.
- Agency EM. PRAC review does not confirm increase in heart problems with testosterone medicines. [ 2014 Oct 10]. Available from: http://www ema europa eu/ema/index jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/human_referral_prac_000037 jsp&mid=WC0b01ac05805c516f, 2014.
- Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836.
- Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Plos One. 2014;9(1):e85805.
- The Ontario Drug Policy Research Network Drug Class Review on Tesosterone Replacement Therapy. Available from: http://odprn.ca/drug-class-review/completed-reviews/testosterone-replacement-therapy/, 2015.
- Wells G, Elliott J, Kelly S, et al. Testosterone in the treatment of androgen deficiency. Available from: http://odprn.ca/drug-class-review/completed-reviews/testosterone-replacement-therapy/, 2015.
- Szeinbach SL, Seoane-Vazquez E, Summers KH. Development of a men’s Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence. 2012;6:631.
- Abadilla KA, Dobs AS. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs. 2012;72(12):1591–1603.
- Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–1466.
- Gan EH, Pattman S, Pearce HS, et al. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf). 2013;79(4):564–570.
- Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835–842.
- Piszczek J, Mamdani M, Antoniou T, et al. The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men. PLoS One. 2014;9(7):e98003.
- Vitry AI, Mintzes B. Disease mongering and low testosterone in men: the tale of two regulatory failures. Med J Aust. 2012;196(10):619–621.
- Eggertson L. Brouhaha erupts over testosterone-testing advertising campaign. CMAJ: Can Med Assoc J. 2011;183(16):e1161.
- Search OMoHaL-TCF. Ontario Drug Benefit formulary/comparative drug index. 2016. Available from: https://www.healthinfo.moh.gov.on.ca/formulary/SearchServlet.
- Walsh T, Shores M, Fox A, et al. Recent trends in testosterone testing, low testosterone levels, and testosterone treatment among Veterans. Andrology. 2015;3(2):287–292.
- Amadio A, Lee K, Yao Z, et al. Public drug coverage and its impact on triptan use across canada: a population‐based study. Headache: the Journal of Head and Face Pain. 2015;Suppl 4:212–220.
- Khan S, Moore JE, Gomes T, et al. The ontario drug policy research network: bridging the gap between research and drug policy. Health Policy. 2014;117(3):392–398.
- Burden A, Tadrous M, Calzavara A, et al. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int. 2015;26(5):1525–1533.
- Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust. 2012;196(10):642.
- Mamdani M, McNeely D, Evans G, et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med. 2007;120(10):893–900.
- Moore NH. Effects of evidence-based formulary restrictions at a Veterans Affairs medical center. Formulary. 2006;41(12):657–668.
- Hashim S, Gomes T, Juurlink D, et al. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones. Journal Population Therapeutics Clinical Pharmacology= Journal De La Therapeutique Des Populations De La Pharamcologie Clinique. 2012;20(3):e238–42.
- Moon JC, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Frontiers Pharmacol. 2014;219:5.
- Serebruany VL, DiNicolantonio JJ. Changes of ticagrelor formulary tiers in the USA: targeting private insurance providers away from government-funded plans. Cardiology. 2013;126(3):187–190.